Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2Unknown 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 8Other hematologic neoplasm 6Tumor-Agnostic 4Thoracic 3Other solid neoplasm 3Lymphoid 3Genitourinary 3Gastrointestinal 3Myeloid 2Head & Neck 2Gynecologic 2Dermatologic 2Plasma cell 1Classical hematology 1CNS 1

Conditions

Skin Neoplasms 2Melanoma 2

Interventions

Ipilimumab 123pembrolizumab 100Nivolumab 100aldesleukin 89Cyclophosphamide 85fludarabine phosphate 64Interleukin-2 58Dacarbazine 573-ingenyl angelate 42Vemurafenib 39Temozolomide 39Imiquimod 39trametinib 37sargramostim 37Peripheral Blood Stem Cell Transplantation 36incomplete Freund's adjuvant 35dabrafenib 32fludarabine 31Radiotherapy 31Aminolevulinic Acid 30Bevacizumab 29Carboplatin 28Whole-Body Irradiation 25Photochemotherapy 25Paclitaxel 25Filgrastim 25Biopsy 25Interferon-alpha 24Cisplatin 23Sorafenib 22

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Tablets × Dermatologic × Clear all
NCT00083239 2007-06-08

Study of Talabostat in Advanced Melanoma

Point Therapeutics

Phase 2 Completed
Dermatologic

Melanoma, Skin Neoplasms

NCT00083252 2007-06-08

Study of Talabostat and Cisplatin in Advanced Melanoma

Point Therapeutics

Phase 2 Completed
Dermatologic

Melanoma, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡